STAAR Surgical Company
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STAA research report →
Range $23 – $34
Price Chart
About the company
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness.
- CEO
- Warren Foust
- IPO
- 1992
- Employees
- 921
- HQ
- Lake Forest, CA, US
Get TickerSpark's AI analysis on STAA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.22B
- P/E
- 2503.00
- Fwd P/E
- 70.02
- PEG
- -56.54
- P/S
- 3.83
- P/B
- 3.36
- EV/EBITDA
- 67.95
- Div Yield
- 0.00%
- Gross Margin
- 73.15%
- Op Margin
- 6.71%
- Net Margin
- 0.16%
- ROE
- 0.15%
- ROIC
- 0.50%
Latest fiscal year · YoY change
- Revenue
- $239.44M-23.7%
- Gross Profit
- $182.42M-23.9%
- Op Income
- $-45,946,000
- Net Income
- $-80,448,000-298.1%
- EPS
- $-1.62-295.1%
- OCF Growth
- -317.7%
- FCF Growth
- -422.2%
- 52W High
- $35.87
- 52W Low
- $15.59
- 50D MA
- $23.12
- 200D MA
- $24.04
- Beta
- 1.20
- RSI (14)
- 52
- Avg Volume
- 837.66K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
STAAR posted record 9-month revenue and positive bottom-line results, but Q3 margins were pressured by ERP, freight, tariffs, and inventory issues while China growth remained mix- and ASP-driven.· November 4, 2026
- Q3 net sales were $83.4 million, down 12% year over year, but up 21% versus the prior-year base excluding China deferred sales.
- China net sales were $39.3 million; excluding deferred sales, China grew 31%, with all growth coming from higher average selling prices driven by V5/EVO+ and toric mix.
- Gross margin fell to 70.9% from 82.2% a year ago, hurt by ERP-related low production, freight, tariffs, and inventory provisions; management expects Q4 margin to improve.
- GAAP net income was $5.6 million, or $0.11 per diluted share; adjusted EBITDA was $14.4 million, and cash/investments rose to $206.4 million with no debt.
- Management kept full-year 2026 operating expense target at $225 million and said record 9-month revenue supports strong full-year GAAP net income and free cash flow.
Third-quarter net sales were $83.4 million, down 12% year over year. Excluding the $25.9 million of China deferred sales in the prior-year quarter, prior-year Q3 net sales were $68.8 million, implying 21% growth on that basis. China net sales were $39.3 million versus $55.8 million a year ago; excluding deferred sales, China grew 31% from $29.9 million, and management said all of that growth came from higher average selling prices. Outside China, net sales rose 13% to $44.1 million. Gross margin was 70.9% versus 82.2% a year ago; excluding the deferred-sales effect, prior-year gross margin would have been 75.5%. GAAP net income was $5.6 million, or $0.11 per diluted share, versus $8.9 million, or $0.18 per diluted share, last year. Adjusted EBITDA was $14.4 million versus $34.7 million last year. Cash, cash equivalents, and investments available for sale totaled $206.4 million, and the company had no debt. Forward, management expects Q4 gross margin to be above Q3 and said gross margin should continue improving in 2027 as unit costs improve; they also reiterated the $225 million adjusted operating expense target for the full year and said 2026 should deliver strong GAAP net income and free cash flow.
Warren Foust framed the quarter around three priorities set at the start of the year: revenue growth, profit expansion, and innovation acceleration. He said STAAR has made progress on all three, citing record 9-month revenue, stronger profitability, and early steps in presbyopia and other new products. His tone was constructive and confident, emphasizing the long-term shift from lasers to lenses, stronger EVO+ adoption in China, and a larger opportunity in the U.S. and other markets to bring more patients off the sidelines.
Deborah Andrews focused on the mechanics of the quarter and the margin bridge. She highlighted that Q3 gross margin of 70.9% was pressured by higher manufacturing costs tied to low Q2 production during ERP implementation, freight, tariffs on U.S.-made products sold into China, and inventory provisions. She said unit costs should stay elevated for the rest of the year, but both manufacturing facilities are now at full capacity and margins should improve in 2027; she also noted Q4 gross margin should benefit from lower tariffs and smaller inventory provisions. On the balance sheet, she pointed to $206.4 million of cash and investments and no debt, and said the company remains on track for the $225 million adjusted operating expense target.
Analysts focused heavily on China demand, inventory, and whether unmet demand would create Q4 restocking. Management said distributor inventory is already below its 6-month target, did not expect large restocking orders, and said any missed demand was due partly to supply constraints and the complexity of Collamer manufacturing rather than distributors actively drawing down inventory. Questions also centered on whether China growth was truly volume-driven; management clarified that Q3 China growth was entirely ASP-driven, while distributor sell-out/unit volume was about 12.5% through 9 months and was being used as a proxy for underlying demand. Analysts also asked about the new presbyopia lenses and 2027 guidance; management said first-in-human trials for two Collamer-based presbyopia products should start in the next few months, subject to regulatory approvals, but declined to give 2027 guidance.
The call reinforced that demand for EVO+ and toric lenses is still outpacing supply, especially in China, where management sees continued runway for mix-driven ASP expansion. Outside China, management said the structural shift from laser to lens is supporting growth across regions, with the U.S. posting a third straight quarter above $6 million in sales. The balance sheet is strong, cash is up, the company is debt-free, and management is investing in manufacturing, commercialization, and a presbyopia pipeline.
Margins were materially weaker year over year, and management said unit costs will remain elevated through year-end because of ERP-related production disruption, freight, tariffs, and inventory provisions. China growth is complicated by supply constraints and mix, making it harder to gauge how much is true end-market volume versus pricing; management also said Q4 will likely be seasonally lower in China. The company declined to provide 2027 guidance, and management acknowledged ongoing macro and geopolitical uncertainty.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.2%
- Shares Outstanding
- 50.20M
- Float Shares
- 49.80M
of shares held by institutions
213 13F filers
Buy/sell ratio 3.33. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Broadwood Capital Inc | 16.12M | 0 |
| Blackrock, Inc. | 5.02M | ▼ 1.71M |
| Vanguard Group Inc | 4.23M | ▼ 42.56K |
| Madison Avenue Partners, LP | 4.18M | ▲ 1.73M |
| Yunqi Capital Ltd | 3.26M | 0 |
| Point72 Asset Management, L.P. | 2.44M | ▲ 1.61M |
| Goldman Sachs Group Inc | 2.15M | ▲ 1.08M |
| Vanguard Portfolio Management LLC | 1.83M | ▼ 152.50K |
| Anatole Investment Management Ltd | 1.65M | ▲ 50.00K |
| State Street Corp | 1.37M | ▼ 400.19K |
| Vanguard Capital Management LLC | 1.32M | ▼ 229.32K |
| Two Seas Capital LP | 1.30M | ▲ 240.57K |
Held by 305 ETFs
Biggest fund positions in STAA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 26 | Foust Warren | other | 131,830 |
| Aug 14, 26 | Foust Warren | other | 123,659 |
| Aug 14, 26 | Foust Warren | other | 3,730 |
| Aug 14, 26 | Foust Warren | other | 3,666 |
| Aug 14, 26 | Foust Warren | other | 1,865 |
| Aug 14, 26 | Foust Warren | other | 3,666 |
| Aug 14, 26 | Foust Warren | other | 7,331 |
| Aug 14, 26 | Foust Warren | other | 7,331 |
| Aug 14, 26 | ANDREWS DEBORAH J | other | 5,233 |
| Aug 14, 26 | ANDREWS DEBORAH J | other | 5,233 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STAA coverage
Recent articles, reports, and earnings notes.
No research on STAA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STAA report →What STAAR Surgical (STAA) Said on Its Q3 Earnings Call
defenseworld.net · Nov 5
What STAAR Surgical (STAA) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
STAAR Surgical Company (STAA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates
zacks.com · Nov 4
STAAR Surgical Reports Third Quarter 2026 Results
businesswire.com · Nov 4
STAAR Surgical Appoints Pascal Aeschlimann as Vice President of Asia Pacific
businesswire.com · Oct 29
Earnings Preview: Staar Surgical (STAA) Q3 Earnings Expected to Decline
zacks.com · Oct 28
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of STAAR Surgical Company (NASDAQ: STAA)
prnewswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.